Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.53, p.450-456, 2006 |
||
Title: Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax | ||
Author: S.Y., KANG ; Y.T., OH ; J.H., HAN ; J.-H., CHOI ; H.-Y., LIM ; H.I., KIM ; H.-W., LEE ; J.H., JANG ; J.S., PARK ; H.C., KIM ; S., KANG ; M., CHUN | ||
Abstract: A randomized trial has demonstrated that concurrent
chemoradiotherapy (CRT) is superior to radiotherapy (RT) alone in
locally advanced nasopharyngeal cancer (NPC).
Our study comprise 35 patients with locally advanced NPC (stage I:
1, II: 12, III: 7, IV: 15) with 1 cycle of induction chemotherapy
(5-fluorouracil 1,000 mg/m2/day and cisplatin 20 mg/m2/day, days 1–
4) followed by concurrent CRT starting on
day 22. Concurrent CRT consisted of RT (70 Gy/35 fractions for 7
weeks) with cisplatin 20 mg/m2/day for 4 days on weeks
1, 4, 7 of RT.
Complete response (CR) was achieved in 33 patients (94%). Four-
year progression-free survival (PFS) and overall survival
(OS) of all patients were 57% and 65%, respectively. In analysis
of prognostic factors, low expression of bax was the
most significant independent predictor of poor prognosis in both
PFS (p=0.002) and OS (p=0.008).
In conclusion, the outcome of patients treated with this combined
therapeutical modality appears to be comparable with
that of Intergroup 0099 trial with high CR rate. Low expression of
bax was significantly associated with poor PFS and OS.
|
||
Keywords: nasopharyngeal cancer, chemoradiotherapy, bax, low expression, prognosis | ||
Year: 2006, Volume: 53, Issue: | Page From: 450, Page To: 456 | |
|
download file |
|